What if we could finally crack the code on treating brain cancer by opening the door that’s blocked 98% of therapies? In this episode, Dr. Michael Canney, Chief Scientific Officer of Carthera, reveals how SonoCloud—a revolutionary ultrasound implant—temporarily opens the blood-brain barrier to deliver chemotherapy directly to tumors like glioblastoma. With over 100 patients enrolled in a Phase III trial across 40 global sites, this isn’t just a bold idea—it’s happening now.

Michael also shares real-world lessons in scaling trials, FDA navigation, and aligning science with commercial success. If you’re passionate about disruptive innovation in neuro-oncology, you’ll want to hear how Carthera is changing the game.